In the NewsBioSpace: Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M In the News / lsc-webmaster
In the NewsCrain’s Chicago Business: Cour Pharma lands $900 million licensing agreement with Roche unit In the News / lsc-webmaster
In the NewsBioWorld: Tolerogenic assets at heart of Cour-Genentech $940M autoimmune deal In the News / lsc-webmaster
In the NewsBioprocess Online: Internalizing Nanoparticle Therapeutic Development In the News / lsc-webmaster
In the NewsMyasthenia Gravis News: First generalized MG patient dosed in immune-modifying therapy trial In the News / lsc-webmaster
In the NewsLiver Disease News: CNP-104 shown to safely reduce liver scarring in PBC Phase 2 trial In the News / lsc-webmaster
In the NewsDrug Target Review: Treating immune-mediated diseases with nanoparticles In the News / lsc-webmaster
In the NewsMM+M: Cour Pharmaceuticals CEO John Puisis discusses $105M funding round In the News / lsc-webmaster
In the NewsMyasthenia Gravis News: $105M raised to support clinical trial of CNP-106 in gMG patients In the News / lsc-webmaster
